Man

Rodrigo Alonso

Director Jefe Departamento

Clínica Las Condes

Santiago, Chile

Líneas de Investigación


Lípidos, Hipercolesterolemia Familiar, Nutrición Clínica, medicina interna

Educación

  •  Medicina, UNIVERSIDAD AUTONOMA DE MADRID. España, 1994
  •  Nutrición Clínica, UNIVERSIDAD AUTONOMA INDOAMERICA. Chile, 1994
  •  Médico Cirujano, UNIVERSIDAD DE VALPARAISO. Chile, 1987

Experiencia Académica

  •   Profesor Titular Part Time

    UNIVERSIDAD DE VALPARAISO

    Medicina

    Valparaiso, Chile

    1993 - 2003

Experiencia Profesional

  •   Jede de Departamento Full Time

    Clínica Las Condes

    Santiago, Chile

    2006 - A la fecha

Difusión y Transferencia


Director del Simposio Internacional en Hiperlipemias Genéticas y Riesgo Cardiovascular. Madrid 2008
Miembro del Comité de Colaboración Internacional Proyecto MED-PED (Make early diagnosis. prevent early diseases) para la detección y tratamiento de la Hipercolesterolemia Familiar Hetercigota
Director y Tutor del Curso “on-line” Actualización en el diagnóstico y tratamiento de las hiperlipemias familiares acreditado con 7,1 créditos por la Agencia Laín Entralgo (1ª y 2ª edición nacional y 1ª edición Castilla y León) 2012-2013
Director III Simposio Red Iberoamericana de Hipercolesterolemia Familiar. Santiago de Chile, 24-26 septiembre 2015.
Director del Simposio IAS-Grupo Chileno de Trabajo en Ateroesclerosis en el Congreso Interamericano de Cardiología, Santiago de Chile 6 de diciembre 2015.
Director del Simposio IAS-Grupo Chileno de Trabajo en Ateroesclerosis en las XI Jornadas de Nutrición Clínica, Obesidad y Metabolismo. El reto de la prevención cardiovascular. Santiago de Chile 20 de mayo de 2016
Director del 1 Curso de la Sociedad Médica de Santiago y Grupo Chileno de Trabajo en Ateroesclerosis. Actualización en el manejo de los factores de riesgo cardiovascular: De la teoría a la práctica clínica. Santiago de Chile 16 de junio de 2016.
Director del 2 Curso de la Sociedad Médica de Santiago y Grupo Chileno de Trabajo en Ateroesclerosis. Actualización en el manejo de los factores de riesgo cardiovascular: De la teoría a la práctica clínica. Santiago de Chile 14,15 de julio de 2017.
Director de Curso de Dislipidemias Fundación Lucas Sierra; Viña del Mar 13 y 14 abril 2018
Líder Nacional Proyecto European Atherosclerosis Society Familial Hypercholesterolemia Studies Collaboration (EAS FHSC 2017-2019)
Member at large (miembro del Board) de la International Atherosclerosis Society



 

Article (70)

Adults with familial hypercholesterolaemia have healthier dietary and lifestyle habits compared with their non-affected relatives: the SAFEHEART study
Diagnosis and Management of Statin Intolerance
Liquid Biopsy of Extracellular Microvesicles Maps Coronary Calcification and Atherosclerotic Plaque in Asymptomatic Patients With Familial Hypercholesterolemia
Value of Measuring Lipoprotein(a) During Cascade Testing for Familial Hypercholesterolemia
Atherosclerotic cardiovascular disease risk assessment in familial hypercholesterolemia: does one size fit all?
Coronary computed tomographic angiography findings and their therapeutic implications in asymptomatic patients with familial hypercholesterolemia. Lessons from the SAFEHEART study
Familial Hypercholesterolaemia Diagnosis and Management
Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)
Response to letter entitled Coronary computed tomography angiogram in familial hypercholesterolemia: A double edge sword
Sleeve Gastrectomy Outcomes in Patients with BMI Between 30 and 35-3 Years of Follow-Up
Atherogenic Dyslipidemia in Latin America: Prevalence, causes and treatment Expert's position paper made by The Latin American Academy for the Study of Lipids (ALALIP) Endorsed by the Inter-American Society of Cardiology (IASC), the South American Society of Cardiology (SSC), the Pan-American College of Endothelium (PACE), and the International Atherosclerosis Society (IAS)
Attainment of LDL Cholesterol Treatment Goals in Children and Adolescents With Familial Hypercholesterolemia. The SAFEHEART Follow-up Registry
Clinical and molecular aspects of familial hypercholesterolemia in Ibero-American countries
Cost-effectiveness of a cascade screening program for the early detection of familial hypercholesterolemia
Mutational analysis and genotype-phenotype relation in familial hypercholesterolemia: The SAFEHEART registry
Plasma PCSK9 measurement by liquid chromatography-Tandem mass spectrometry and comparison with conventional ELISA
Predicting Cardiovascular Events in Familial Hypercholesterolemia The SAFEHEART Registry (Spanish Familial Hypercholesterolemia Cohort Study)
ApoL1 levels in high density lipoprotein and cardiovascular event presentation in patients with familial hypercholesterolemia
Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia 5-Year SAFEHEART Registry Follow-Up
Clinical and molecular characteristics of homozygous familial hypercholesterolemia patients: Insights from SAFEHEART registry
Coronary Heart Disease, Peripheral Arterial Disease, and Stroke in Familial Hypercholesterolaemia: Insights From the SAFEHEART Registry (Spanish Familial Hypercholesterolaemia Cohort Study)
PCSK9 and lipoprotein (a) levels are two predictors of coronary artery calcification in asymptomatic patients with familial hypercholesterolemia
Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration
Clinically used selective oestrogen receptor modulators increase LDL receptor activity in primary human lymphocytes
Diagnosis and treatment of familial hypercholesterolemia in Spain: Consensus document
Familial hypercholesterolaemia: A global call to arms
High levels of TSP1(+)/CD142(+) platelet-derived microparticles characterise young patients with high cardiovascular risk and subclinical atherosclerosis
Homozygous familial hypercholesterolemia. First case in Spain treated with lomitapide, an inhibitor of the synthesis of lipoproteins with apolipoprotein B
rs11613352 Polymorphism (TT Genotype) Associates with a Decrease of Triglycerides and an Increase of HDL in Familial Hypercholesterolemia Patients
Statins do not increase the risk of developing type 2 diabetes in familial hypercholesterolemia: The SAFEHEART study
Treating homozygous familial hypercholesterolaemia in a real-world setting=> experiences with lomitapide
Treating homozygous familial hypercholesterolemia in a real-world setting: Experiences with lomitapide
Diagnosis and treatment of familial hypercholesterolemia in Spain=> Consensus document.
Familial combined hyperlipidemia: Consensus document
Familial combined hyperlipidemia=> Consensus document
Homozygous familial hypercholesterolemia. First case in Spain treated with lomitapide, an inhibitor of the synthesis of lipoproteins with apolipoprotein B.
Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation
Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation
Lipoprotein(a) levels in Familial Hipercholesterolaemia=> an important predictor for cardiovascular disease independent of the type of LDL-receptor mutation
New Lipid Lowering Agents
Quality of life in a cohort of familial hypercholesterolemia patients from the south of Europe
Retinol-binding protein 4 levels and susceptibility to ischaemic events in men
rs1801275 Interleukin-4 receptor alpha polymorphism in familial hypercholesterolemia
Screening for Familial Hypercholesterolemia=> a Model for Preventive Medicine.
Early diagnosis and treatment of Familial Hypercholesterolemia=> Can we improve patient outcomes
Lipid-lowering therapy with statins reduces microparticles shedding from endothelium, platelets and inflammatory cells indicating protection against cell activation.
Detection of subclinical atherosclerosis in familial hypercholesterolemia using non-invasive imaging modalities
Differential proteomic distribution of TTR (pre-albumin) forms in serum and HDL of patients with high cardiovascular risk
Extreme Xanthomastosis in patients with both familial hipercolesterolemia and Cerebrotendineous Xanthomatosis
Influence of Lipoprotein (a) on Inflammatory Biomarkers in Metabolic Syndrome
LRP1 Gene Polymorphisms Are Associated With Premature Risk of Cardiovascular Disease in Patients With Familial Hypercholesterolemia.
Omega-3 fatty acids and blood pressure
Quality of life in a cohort of familial hypercholesterolemia patients from the south of Europe
Validation of a food frequency questionnaire in Spanish patients with familial Hypercholesterolaemia
Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolemia Longitudinal Cohort Study (SAFEHEART).
Polymorphism at the TRIB1 gene modulates plasma lipid levels=> Insight from the spanish familial hypercholesterolemia cohort study.
R353Q polymorphism in the factor VII gene and cardiovascular risk in Heterozygous Familial Hypercholesterolemia=> a case-control study.
Genetic variations at ABCG5/G8 genes modulate plasma lipids concentrations in patients with familial hipercolesterolemia.
Higher Incidence of Mild Cognitive Impairment in Familial Hypercholesterolemia
Análisis de coste-efectividad de un programa de cribado genético en familiares directos de pacientes con hipercolesterolemia familiar en España.
Genetic diagnosis of familial hypercholesterolemia using a DNA-array based platform
Genetic Diagnosis of Familial Hypercholesterolemia using a DNA-array based platform
Cardiovascular disease in familial hypercholesterolaemia=> Influence of low-density lipoprotein receptor mutation type and classic risk factors
Cost-effectiveness of managing familial hypercholesterolemia using atorvastatin-based preventive therapy.
Molecular diagnosis and combined lipid lowering therapy of heterozygous familial hypercholesterolemia. Report of one case
Comparison of DNA array platform vs DNA sequencing as genetic diagnosis tools for familial hypercholesterolemia
High frequency of APOB gene mutations causing familial hypobetalipoproteinaemia in patients of Dutch and Spanish descent
Reliable low-density DNA array based on allele-specific probes for detection of 118 mutations causing familial hypercholesterolemia
Tendon xanthomas in familial hypercholesterolemia are associated with cardiovascular risk independently of the low-density lipoprotein receptor gene mutation
Circulating CD45+/CD3+ lymphocyte-derived microparticles map lipid-rich atherosclerotic plaques in Familial hypercholesterolemia patients.

BookWhole (1)

The Genetics of Obesity

EditorialMaterial (1)

Extreme xanthomatosis in patients with both familial hypercholesterolemia and cerebrotendinous xanthomatosis

Review (5)

Statin-associated muscle symptoms: position paper from the Luso-Latin American Consortium
Cardiac computed tomography imaging in familial hypercholesterolaemia: Implications for therapy and clinical trials
New lipid lowering agents
Nuevos fármacos para el tratamiento de la hipercolesterolemia
Metabolic Syndrome. Clinical and pathophysiological basis for a rational therapeutical approach
49
Rodrigo Alonso

Director Jefe Departamento

Nutrición Clínica

Clínica Las Condes

Santiago, Chile

6
Ada Cuevas

Médico

Nutrición Clínica

CLINICA LAS CONDES

Santiago, Chile

1
Sylvia Asenjo

Profesor Titular

Pediatría

Universidad de Concepción

Concepción, Chile

1
Fernando Lanas

Profesor titular

Medicina Interna

UNIVERSIDAD DE LA FRONTERA

Temuco, Chile

1
MONICA ACEVEDO

Titular Professor

Division of Cardiovascular Diseases

P. UNIVERSIDAD CATOLICA DE CHILE

SANTIAGO, Chile

1
Attilio Rigotti

Full Professor

Nutrition, Diabetes and Metabolism

Pontificia Universidad Católica de Chile

Santiago, Chile

1
Attilio Rigotti

Full Professor

Nutrition, Diabetes and Metabolism

PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE - ESCUELA DE MEDICINA - DEPTO DE GASTROENTEROLOGÍA

Santiago, Chile

1
Patricio Lamoza

Cirujano

Cirugia

Hospital El Carmen

Santiago, Chile